Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin

Blood

Volumn 100, Issue 10, 2002, Pages 3790-3796

  Matsui, Neil M ^a,b,c   Varki, Ajit ^a,b,c   Embury, Stephen H ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b N California Sickle Cell Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; HEPARIN; PADGEM PROTEIN; RECOMBINANT PROTEIN; THROMBIN;

ARTICLE; BLOOD VESSEL OCCLUSION; CELL ADHESION; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SICKLE CELL; VASCULAR ENDOTHELIUM;

EID: 0037111637     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0626     Document Type: Article

References (76)

1. Embury SH, Hebbel RP, Steinberg MH, Mohandas N, Pathogenesis of vasoocclusion. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York, NY: Raven Press, Ltd; 1994:311-326.
2. Reed W, Vichinsky EP. New considerations in the treatment of sickle cell disease. Annu Rev Med. 1998;49:461-474.
3. Steinberg MH, Rodgers GP. Pathophysiology of sickle cell disease: Role of cellular and genetic modifiers. Semin Hematol. 2001;38:299-306.
4. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762-769.
5. Hebbel RP, Eaton JW, Steinberg MH, White JG. Erythrocyte/endothelial interactions in the pathogenesis of sickle-cell disease: A "real logical" assessment. Blood Cells. 1982;8:163-173.
6. Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: Pathophysiological implications. Proc Natl Acad Sci U S A. 1989;86:3356-3360.
7. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia: A possible determinant of disease severity. N Engl J Med. 1980;302:992-995.
8. Hebbel RP. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med. 2000;342:1910-1912.
9. Harlan JM. Introduction: Anti-adhesion therapy in sickle cell disease [comment]. Blood. 2000;95:365-367.
10. Wun T. The role of inflammation and leukocytes in the pathogenesis of sickle cell disease. Hematology. 2001;5:403-412.
11. Frenette PS. Sickle cell vaso-occlusion: Multistep and multicellular paradigm. Curr Opin Hematol. 2002;9:101-106.
12. Setty BN, Kulkarni S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood. 2002;99:1564-1571.
13. Hebbel RP. Perspectives series: Cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 1997;99:2561-2564.
14. Rodgers GP, Schechter AN, Noguchi CT, Klein HG, Nienhuis AW, Bonner RF. Periodic microcirculatory flow in patients with sickle-cell disease. N Engl J Med. 1984;311:1534-1538.
15. Lipowsky HH, Sheikh NU, Katz DM. Intravital microscopy of capillary hemodynamics in sickle cell disease. J Clin Invest. 1987;80:117-127.
16. Embury SH, Mohandas N, Paszty C, Cooper P, Cheung AT. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. J Clin Invest. 1999;103:915-920.
17. Montes RAO, Eckman JR, Hsu LL, Wick TM. Sickle erythrocyte adherence to endothelium at low shear: The role of shear stress in propagation of vaso-occlusion. Am J Hematol. 2002;70:216-227.
18. Silverstein RL. The vascular endothelium. In: Gallin JI, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:207-225.
19. Shiu YT, Udden MM, McIntire LV. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood. 2000;95:3232-3241.
20. Francis RB Jr. Elevated fibrin D-dimer fragment in sickle cell anemia: Evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 1989;19:105-111.
21. Kurantsin-Mills J, Ibe BO, Natta CL, Raj JU, Siegel RS, Lessin LS. Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation. Br J Haematol. 1994;87:580-585.
22. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
23. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
24. Manodori AB, Matsui NM, Chen JY, Embury SH. Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation. Blood. 1998;92:3445-3454.
25. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001;98:1955-1962.
26. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859-873.
27. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1999.
28. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 1985;101:880-886.
29. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem. 1989;264:7768-7771.
30. Lorant DE, Patel KD, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: A juxtacrine system for adhesion and activation of neutrophils. J Cell Biol. 1991;115:223-234.
31. Closse C, Seigneur M, Renard M, Pruvost A, Dumain P, Belloc F, Boisseau MR. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. Haemostasis. 1996;26:177-181.
32. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411-420.
33. Turhan A, Weiss LA, Monhandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm. Proc Natl Acad Sci U S A. 2002;99:3047-3051.
34. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of hepadn and heparan sulfate glycosaminoglycans with the selectins: Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998;101:877-889.
35. Gupta K, Gupta P, Solovey A, Hebbel RP. Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Biochim Biophys Acta. 1999;1453:63-73.
36. Barabino GA, Liu XD, Ewenstein BM, Kaul DK. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Blood. 1999;93:1422-1429.
37. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108:258S-275S.
38. Francis RB Jr. Platelets, coagulation, and fibrinolysis in sickle cell disease: Their possible role in vascular occlusion. Blood Coagul Fibrinolysis. 1991;2:341-353.
39. Chaplin H Jr, Monroe MC, Malecek AC, Morgan LK, Michael J, Murphy WA. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J. 1989;66:574-584.
40. Abbitt KB, Rainger GE, Nash GB. Effects of fluorescent dyes on selectin and integrin-mediated stages of adhesion and migration of flowing leukocytes. J Immunol Methods. 2000;239:109-119.
41. Patel N, Brinkman-Van der Linden EC, Altmann SW, et al. OB-BP1/Siglec-6 a leptin- and sialic acid-binding protein of the immunoglobutin superfamily. J Biol Chem. 1999;274:22729-22738.
42. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859-873.
43. Frangos JA, McIntire LV, Eskin SG. Shear stress induced stimulation of mammalian cell metabolism. Biotechnology and Bioengineering. 1988;32:1053-1060.
44. Turitto VT. Blood viscosity, mass transport, and thrombogenesis. Prog Hemost Thromb. 1982;6:139-177.
45. Wagener FA, Abraham NG, van Kooyk Y, de Witte T, Figdor CG. Heme-induced cell adhesion in the pathogenesis of sickle-cell disease and inflammation. Trends Pharmacol Sci. 2001;22:52-54.
46. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell. 1994;76:301-314.
47. Lutty GA, Taomoto M, Cao J, et al. Inhibition of TNF-alpha-induced sickle RBC retention in retina by a VLA-4 antagonist. Invest Ophthalmol Vis Sci. 2001;42:1349-1355.
48. Spring FA, Parsons SF, Ortlepp S, Olsson ML, Sessions R, Brady RL, Anstee DJ. Intercellular adhesion molecule-4 binds alpha(4)beta(1) and alpha(V)-family integrins through novel integrin-binding mechanisms. Blood. 2001;98:458-466.
49. Joneckis CC, Ackley RL, Orringer EP, Wayner EA, Parise LV. Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood. 1993;82:3548-3555.
50. Kaul DK, Tsai HM, Liu XD, Nakada MT, Nagel RL, Coller BS. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor [see comments]. Blood. 2000;95:368-374.
51. Embury SH, Matsui NM. Endothelial gap formation, and erythrocyte adhesion. In: Weir EK, Reeve HL, Reeves JT, eds. Interactions of Blood and the Pulmonary Circulation. Armonk, NY: Futura Publishing Company; 2002:35-68.
52. Brittain JE, Mlinar KJ, Anderson CS, Orringer EP, Parise LV. Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. J Clin Invest. 2001;107:1555-1562.
53. Brittain JE, Mlinar KJ, Anderson CS, Orringer EP, Parise LV. Integrin-associated protein is an adhesion receptor on sickle red blood cells for immobilized thrombospondin. Blood. 2001;97:2159-2164.
54. Sugihara K, Sugihara T, Mohandas N, Hebbel RP, Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood. 1992;80:2634-2642.
55. Lee K, Gane P, Roudot-Thoraval F, et al. The nonexpression of CD36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia. Blood. 2001;98:966-971.
56. Thevenin BJM, Crandall I, Ballas SK, Sherman IW, Shohet SB. Band 3 peptides block the adherence of sickle cells to endothelial cells in vitro. Blood. 1997;90:4172-4179.
57. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 1993;82:3253-3258.
58. Engelberg H. Actions of heparin that may affect the malignant process. Cancer. 1999;85:257-272.
59. Lowe JB, Ward PA. Therapeutic inhibition of carbohydrate-protein interactions in vivo. J Clin Invest. 1997;99:822-826.
60. Bruehl RE, Dasgupta F, Katsumoto TR, et al. Polymerized liposome assemblies: Bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands. Biochemistry. 2001;40:5964-5974.
61. Bertozzi CR, Kiessling LL. Chemical glycobiology. Science. 2001;291:2357-2364.
62. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
63. Styles LA, Larkin SK, Sweeters N, Simon J, Kuypers FA, Vichinsky EP. Abnormal response to low molecular weight heparin in sickle cell disease [abstract]. Blood. 1999;94:27b.
64. Lee Y, Nam JH, Shin HC, Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation. 2001;104:3116-3120.
65. Hiebert LM, Wice SM, Ping T, Hileman RE, Capila I, Linhardt RJ. Tissue distribution and antithrombotic activity of unlabeled or 14C-labeled porcine intestinal mucosal heparin following administration to rats by the oral route. Can J Physiol Pharmacol. 2000;78:307-320.
66. Hiebert LM, Wice SM, McDuffie NM, Jaques LB. The heparin target organ - The endothelium. Studies in a rat model. Q J Med. 1993;86:341-348.
67. Hiebert LM, Wice SM, Jaques LB. Antithrombotic activity of oral unfractionated heparin. J Cardiovasc Pharmacol. 1996;28:26-29.
68. Pineo GF, Hull RD, Marder VJ. Orally active heparin and low-molecular-weight heparin. Curr Opin Pulm Med. 2001;7:344-348.
69. Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastatasis: Rationale for clinical studies in humans. Semin Thromb Hemostasis. 2002;28:53-66.
70. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001;98:3352-3357.
71. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A. 2002;99:2193-2198.
72. Antonucci R, Walker R, Herion J, Orringer E. Enhancement of sickle erythrocyte adherence to endothelium by autologous platelets. Am J Hematol. 1990;34:44-48.
73. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129:507-516.
74. Wun T, Paglieroni T, Field CL, Welborn J, Cheung A, Walker NJ, Tablin F. Platelet-erythrocyte adhesion in sickle cell disease. J Investig Med. 1999;47:121-127.
75. Hofstra TC, Kalra VK, Meiselman HJ, Coates TD. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood. 1996;87:4440-4447.
76. Fadlon E, Vordermeier S, Pearson TC, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood. 1998;91:266-274.